ZTOX

Concord Biotech (CONCORDBIO): Updates

Updates Concord Biotech Limited has informed the Exchange regarding Abbreviated New Drug Application (ANDA) Approval for Mycophenolate Mofetil for Oral Suspension USP, 200 mg/mL'. Concord Biotech Limited has informed the Exchange regarding Abbreviated New Drug Application (ANDA) Approval for Mycophenolate Mofetil for Oral Suspension USP, 200 mg/mL'.

Concord Biotech (CONCORDBIO): Updates

Concord Biotech (CONCORDBIO): Company Update

Company Update We are pleased to inform that the Company has received approval from USFDA for its ANDA for Mycophenolate Mofetil for Oral Suspension USP, 200 mg/mL. We are pleased to inform that the Company has received approval from USFDA for its ANDA for Mycophenolate Mofetil for Oral Suspension USP, 200 mg/mL.

Concord Biotech (CONCORDBIO): Company Update

Concord Biotech (CONCORDBIO): Investor Presentation

Investor Presentation Concord Biotech Limited has informed the Exchange about Investor Presentation Concord Biotech Limited has informed the Exchange about Investor Presentation

Concord Biotech (CONCORDBIO): Outcome of Board Meeting

Outcome of Board Meeting Concord Biotech Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026. Concord Biotech Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.

Concord Biotech (CONCORDBIO): Outcome of Board Meeting

Concord Biotech (CONCORDBIO): Corp. Action

Corp. Action The Board has recommended dividend of Rs. 7.55 per equity share of face value of Rs. 1 each fully paid up for the Financial Year 2025-26. The Board has recommended dividend of Rs. 7.55 per equity share of face value of Rs. 1 each fully paid up for the Financial Year 2025-26.

Concord Biotech (CONCORDBIO): Corp. Action

Concord Biotech (CONCORDBIO): Corp. Action

Concord Biotech (CONCORDBIO): Dividend

Dividend Concord Biotech Limited has informed the Exchange that Board of Directors at its meeting held on May 29, 2026, recommended Final Dividend of Rs. 7.55 per equity share. Concord Biotech Limited has informed the Exchange that Board of Directors at its meeting held on May 29, 2026, recommended Final Dividend of Rs. 7.55 per equity share.